Rafael AguirreSacasa - Standard Biotools Acting Counsel
| LAB Stock | USD 1.71 0.09 5.56% |
Insider
Rafael AguirreSacasa is Acting Counsel of Standard Biotools
| Address | 2 Tower Place, South San Francisco, CA, United States, 94080 |
| Phone | 650 266 6000 |
| Web | https://www.standardbio.com |
Standard Biotools Management Efficiency
The company has Return on Asset of (0.1469) % which means that on every $100 spent on assets, it lost $0.1469. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3725) %, meaning that it generated no profit with money invested by stockholders. Standard Biotools' management efficiency ratios could be used to measure how well Standard Biotools manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Standard Biotools' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.4 M, whereas Total Assets are forecasted to decline to about 228.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nadia Altomare | Sera Prognostics | 53 | |
| William Pitchford | Inotiv Inc | 69 | |
| Dr III | Biodesix | 53 | |
| Heinrich Rder | Biodesix | N/A | |
| Peter Kissinger | Inotiv Inc | 79 | |
| Kimberly Beaty | Inotiv Inc | N/A | |
| Andrew Macan | Neuronetics | 51 | |
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| Michael McGarrity | MDxHealth SA ADR | 61 | |
| Bob Halbert | Star Equity Holdings | N/A | |
| Martin Shirley | Star Equity Holdings | 61 | |
| Michael MD | Sera Prognostics | N/A | |
| DVM DiplomateACVP | Inotiv Inc | 57 | |
| Ron Kalfus | MDxHealth SA ADR | 50 | |
| Sean MD | Sera Prognostics | N/A | |
| Fernanda Beraldi | Inotiv Inc | N/A | |
| Paul Marr | MDxHealth SA ADR | N/A | |
| Richard Coleman | Star Equity Holdings | 67 | |
| Steven Graves | Sera Prognostics | N/A | |
| Richard Anderson | DarioHealth Corp | 55 | |
| Robert Harrison | Sera Prognostics | 58 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.15 |
Standard Biotools Leadership Team
Elected by the shareholders, the Standard Biotools' board of directors comprises two types of representatives: Standard Biotools inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Standard. The board's role is to monitor Standard Biotools' management team and ensure that shareholders' interests are well served. Standard Biotools' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Standard Biotools' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Egholm, CEO President | ||
| Jeffrey Black, Chief Officer | ||
| Shane Bowen, Chief Officer | ||
| Mark Spearman, Sr Communications | ||
| Dr Dphil, CoFounder Board | ||
| Peter DeNardo, Investor Relations | ||
| Stephen Linthwaite, Advisor | ||
| BS MB, Chief Officer | ||
| Hanjoon Kim, Chief Officer | ||
| David Holmes, Investor Relations | ||
| Rafael AguirreSacasa, Acting Counsel | ||
| Adam Taich, Chief Officer | ||
| Sean Mackay, Chief VP | ||
| David King, VP RD | ||
| Jonathan Mickelsen, VP Officer | ||
| Andrew Quong, Chief Officer | ||
| Vikram Jog, Chief Officer | ||
| Angela Peters, Chief Officer |
Standard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Standard Biotools a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 326.2 M | ||||
| Shares Outstanding | 372.26 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 73.30 % | ||||
| Number Of Shares Shorted | 19.54 M | ||||
| Price To Earning | (2.52) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.